Compare IZEA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | CALC |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | 75 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.9M | 9.7M |
| IPO Year | 2010 | 2020 |
| Metric | IZEA | CALC |
|---|---|---|
| Price | $4.45 | $0.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 71.0K | ★ 214.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,099,695.00 | N/A |
| Revenue This Year | $20.81 | N/A |
| Revenue Next Year | $14.86 | N/A |
| P/E Ratio | $54.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $0.46 |
| 52 Week High | $5.86 | $7.20 |
| Indicator | IZEA | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 39.71 |
| Support Level | $4.31 | $0.50 |
| Resistance Level | $4.74 | $0.78 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 83.62 | 41.98 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.